anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All the subjects in the study will receive non surgical periodontal treatment in one session (full-mouth scaling and root planing). Clinical parameters will be assessed in all teeth (except third molars) by one experienced and trained examiner before treatment and every 3 months for 2 years. Visible plaque index (VPI) will be represented a mean percentage of sites with visible plaque calculated for all teeth analyzed (four sites per tooth). Others parameters will be assessed at six sites per tooth using a manual periodontal probe (15mm). Bleeding on probing (BOP) will be represented the mean percentage of sites with bleeding (up to 15 seconds after probing) calculated for all teeth analyzed. Probing depth (PD - distance between the gingival margin and the bottom of the sulcus/pocket), gingival recession (GR - distance between the cementoenamel junction and gingival margin) and clinical attachment level (CAL - distance between the cementoenamel junction and the bottom of the sulcus/pocket) will be represented a mean distance calculated per site for all teeth analyzed. For blood parameters, an outside laboratory will perform all blood analysis. It will be requested for each subject with diabetes (DG) at baseline, each 3 months post-treatment. Fasting plasma glucose (FPG) will be expressed in milligrams per deciliter and HbA1c will be expressed as a percentage. Statistical analysis will be performed using an available software program and the patient will be considered as the unit of analysis.The data will be processed and analyzed by descriptive and inferential statistics, probably nonparametric.
An apparatus, system, and method are disclosed for perfusing an organ. In some implementations, the system may include an organ chamber and a fluid circuit having tubing that couples to the organ within the organ chamber and carries a perfusate to and from the organ. A pump drives the perfusate through the fluid circuit. A replaceable reservoir supplies perfusate to the tubing for use in the fluid circuit. An oxygenator exchanges oxygen gas with waste gas in the perfusate. A hemofilter removes an ultrafiltrate having metabolic waste from the perfusate. A filtrate replacement fluid supplies filtrate replacement fluid to the perfusate. The system may include a controller configured to manage a plurality of perfusion parameters of the fluid circuit to perfuse the organ.
PURPOSE: To obtain a nontoxic composition for preventing and treating paradonthopathy including an extract of an active ingredient of a plant mixture of Chelidonii herba, etc., by water, etc., capable of effectively suppressing fur- formation by fungus, etc., proliferating in the oral vacant, having shrinking and epidermination activities and manifesting antiinflammatory effects, etc. CONSTITUTION: This composition for preventing and treating paradonthopathy comprises an extract of plant mixture obtained by mixing 14-16.5 pts.wt. Chelidonii herba, 2-4 pts.wt. Menthae pip. Fol., 1-2 pts.wt. Calendulae flos, 3-4 pts.wt. Thimia herba and 1.5-2.5 pts.wt. Millefolii herba, optionally 1.7-2.3 pts.wt. Chamomilae, 0.8-1.2 pts.wt. leaf of Melissae fol. and 0.4-0.6 pt.wt. Cariophylli flos or 0.8-1.2 pts.wt. Arnicae flos by water or an aqueous solvent such as 40-50wt.% water-ethanol mixed solvent of 5-10 times amounts as much as the whole amount of the plants, and, if necessary, various additives such as a flavoring agent such as xylit. The composition is capable of reducing fur, and has anti-gingivitis and blood coagulation effects. Further, the composition is preferably used in a form of a dental paste and a mouthwash.
PURPOSE: An eye drop composition containing beta-glucan for treating keratoconjunctivitis is provided to ensure excellent biocompatibility and to resolve the problem of high toxicity. CONSTITUTION: A pharmaceutical composition for treating keratoconjunctivitis or allergic keratoconjunctivitis contains 0.01-10 wt% of beta-1,3 glucan. The beta-1,3 glucan has a beta-1,3 main sugar chain without a beta-1,6 branch. The molecular weight of beta-1,3 glucan is 450-550 kDa. Beta-1,3 glucan is derived from Euglena Gracilis. The pharmaceutical composition additionally contains carboxymethyl cellulose and hyaluronic acid. The composition is an eye drop.
PURPOSE: A pharmaceutical composition containing red ginseng extract for preventing or treating auditory neuropathy is provided to suppress or recover auditory nerve injury. CONSTITUTION: A pharmaceutical composition for preventing or treating auditory neuropathy contains red ginseng extract. The auditory neuropathy is caused by diabetes. The red ginseng extract is prepared using water, alcohol of C1-C4, or a mixture thereof. A food composition for preventing or treating auditory neuropathy caused by diabetes contains the red ginseng extract. The daily dose of the red ginseng extract is 0.0001-100 mg/kg.
The objective of this study is to characterize genes associated either with susceptibility or resistance to the development nasopharyngeal carcinoma (NPC) in a Chinese population where the incidence of NPC is as high as 50 in 100,000. NPC has been and remains a unique model of human malignancy for understanding a multi-step carcinogenic process involving a ubiquitous virus (Epstein-Barr virus), environmental carcinogens, and an NPC susceptibility gene. Up to 95% of all NPC patients at early or late stage of the disease have IgA antibodies directed to the EBV virus VCA (viral capsid antigen). Environmental factors have also been implicated as significant risk factors in the development of NPC. In addition, certain alleles in HLA genes have shown associations with NPC, perhaps in concert with a family of T-cell receptor genes (TCR). Other data suggest that a microsatellite marker on Chromosome 6 may be associated with an NPC-disease associated gene.

We will use a "triad" approach to attempt to dissociate genetic from environmental and viral associations of NPC incidence. Blood samples will be collected from volunteers (probands) and family members (spouse and child and/or parent of patient) at two sites in Guangxi Province, China: the Cancer Research and Control Institute in Wuzhou City; and the Cang Wu County Cancer Hospital, located about 20 miles from Wuzhou. All cases will be EBV/IgA/VCA positive. These triad of samples will provide both control and haplotypic information on cases and controls. A database of pertinent clinical and family information will be created from a questionnaire filled in by hospital staff interviewers. Blood will be separated into plasma and peripheral blood mononuclear cells (PBMCs). Plasma will be tested at the Wuzhou Center for EBV/IgA/VCA. The PBMCs will be viably frozen and transported to the LGD at NCI/FCRDC, where they will be transformed into lymphoblastoid cell lines for extraction of DNA. At the LGD the DNAs will be screened for informative polymorphisms in candidate genes by DNA genotyping methods. Association analyses will be performed to detect linkages between informative polymorphisms in candidate genes by DNA genotyping methods. Association analyses will be performed to detect linkages between informative polymorphisms and clinical and family data. If a marker associated with development of NC is found, there are potential applications in diagnostics and therapy. Further, identification of allelic polymorphisms in genes with a role in NPC progression would offer definitive ties of such genes to the carcinogenic process.

Following this study, the samples will be maintained in our repository and curated through our central Laboratory database. Loss or destruction of these samples wil be recorded in our database and cannot impact the study participants in any way. We understand that studies subsequent to the completion of this protocol will require additional OHSR/IRB approval prior to commencement.
OBJECTIVE: Wound therapies utilizing gene delivery to the skin offer considerable promise owing to their localized treatment benefits and straightforward application. This study investigated the impact of skin electroporation of CYP1A1 shRNA lentiviral particles on diabetic wound healing in a streptozotocin (STZ)-induced rat model.
METHODS: Male Sprague Dawley (SD) rats were made diabetic by injecting STZ and subsequently creating foot skin wounds. The rats were randomly divided into four groups: normal, diabetic foot ulcers (DFU), DFU + control shRNA (electroporation of control shRNA lentiviral particles), and DFU + CYP1A1 shRNA (electroporation of CYP1A1 shRNA lentiviral particles). Wound healing progress was monitored at multiple time points (0, 1, 3, 5, 7, 10, 14 days). On day 14, wound tissue specimens were collected for histological examination. Wound samples collected at days 7 and 14 were used for gene expression analysis via qRT-PCR, assessment of CYP1A1 protein levels using western blotting, and evaluation of oxidative stress markers.
RESULTS: Treatment with CYP1A1 shRNA significantly enhanced diabetic wound healing rates compared to untreated controls over the observation period. Histological analysis revealed improved wound characteristics in the CYP1A1 shRNA-treated group, including enhanced epithelial regeneration, reduced inflammation, and increased collagen deposition, indicative of improved tissue repair. Furthermore, suppression of CYP1A1 corresponded with decreased expression levels of pro-inflammatory cytokines (interleukin-1β, tumor necrosis factor-α, and interleukin-6) and diminished oxidative stress markers (malondialdehyde, superoxide dismutase) within wound tissues.
CONCLUSION: Targeted suppression of CYP1A1 represents a promising therapeutic strategy to enhance diabetic wound healing by modulating inflammation and oxidative stress.
<P>PROBLEM TO BE SOLVED: To provide a method of inhibiting metastasis or maintenance of various cancers.  <P>SOLUTION: The method includes a step for blocking a signaling of a chemokine receptor on a cell. In particular, the method makes use of the fact that certain trafficking of cancers depends upon identified proteins, which serves as markers. Additional methods of screenings are also provided. The metastasis is specific to organs (e.g., a lymph node, bone marrow or skin) or the cancer cells including breast, head and neck, malignant melanoma or prostate thereof.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The invention belongs to the technical fields of biological medicine and molecular biology, and particularly relates to an application of METTL3 in regulating and controlling BRAF-mediated inflammatory reaction. The present invention for the first time found that macrophage specific Mettl3 knockouts inhibited the progression of atherosclerosis and inflammatory responses in vivo. In vitro, METTL3 was found to elevate inflammatory factor levels in ox-LDL induced peritoneal macrophages. Mechanistically, METTL3 was demonstrated to target Braf mRNA, promoting its m6A modification. Further studies have found that YTHDF1 recognizes modified Braf mRNA and promotes its protein expression level. The invention reveals a new mechanism of regulating BRAF in macrophages by METTL3, and provides a potential target point for preventing and treating atherosclerosis cardiovascular diseases, thereby having good potential practical application value.
The present invention provides compositions and methods for inhibiting adhesions. The methods involve administering solutions containing hydrogel precursors such as polysaccharide derivatives, e.g., derivatives of hyaluronic acid, cellulose, or dextran, to a subject at a site where adhesions may form, e.g., as a consequence of surgery, injury, or infection. The hydrogel precursors, e.g., polysaccharide derivatives, become crosslinked following their administration to form a hydrogel that maintains tissue separation. In certain embodiments of the invention one or both solutions contains particles, e.g., polymeric nanoparticles or microparticles, so that a composite hydrogel containing the particles is formed. The solution(s), particle(s), or both, may contain a biologically active agent such as an agent that contributes to inhibiting adhesions. The biologically active agent may be covalently attached to a hydrogel precursor.
The invention relates to a traditional Chinese medicine for treating headache, which is prepared from the following raw materials according to weight portion: 15-40 portions of rhizoma ligustici wallichii, 8-25 portions of ledebouriella seseloides,5-22 portions of angelica dahurica, 3-20 portions of corydalis tuber, 3-20 portions of scorpion, 3-20 portions of mint, 1-7 portions of long pepper and2-15 portions of liquorice. The traditional Chinese medicine has unique and reasonable compatibility, treats various types of headaches and has satisfactory effect. The rhizoma ligustici wallichii in the medicine is a blood gas medicine, can go up to heads and eyes and go down to blood sea, passes the meridian, and pervades the skin. The ledebouriella seseloides is a good medicine for dispersing pathogenic wind, solving pain and stopping pain. The angelica dahurica dehumidifies air and stops pain. The corydalis tuber invigorates the circulation of Qi and blood, and smoothes meridian. The scorpion stops endogenous wind and solves pain, and disperses pathogenic wind and stops pain. The medicines and the rhizoma ligustici wallichii like attracts like, increase the function of pain stopping of the rhizoma ligustici wallichii, and are assistant medicines of the invention. The mint can season over-temperature dryness of the rhizoma ligustici wallichii, the angelica dahurica, the long pepper, and the like. The liquorice goes through the twelve regular meridians, reconciles the medicines, and slowing emergency and stopping pain. The compatibility of the medicines can play especially good effect of dispersing pathogenic wind, invigorating the blood circulation and stopping pain.
As the global obesity rate increases, so does the urgency to find effective anti-obesity drugs. In the search for therapeutic targets, central nervous system (CNS) mechanisms engaged in the regulation of energy expenditure and food intake, such as the opioid and dopamine systems, are crucial. In this study, we examined the effect on body weight of two drugs: bromocriptine (BC), a D2R receptor agonist, and PF-04455242, a selective κ opioid receptor (KOR) antagonist. Using diet-induced obese (DIO) rats, we aimed to ascertain whether the administration of BC and PF-04455242, independently or in combination, could enhance body weight loss. Furthermore, the present work demonstrates that the peripheral coadministration of BC and PF-04455242 enhances the reduction of weight in DIO rats and leads to a decrease in adiposity in a food-intake-independent manner. These effects were based on heightened energy expenditure, particularly through the activation of brown adipose tissue (BAT) thermogenesis. Overall, our findings indicate that the combination of BC and PF-04455242 effectively induces body weight loss through increased energy expenditure by increasing thermogenic activity and highlight the importance of the combined use of drugs to combat obesity.
Temozolomide capsules are a hazardous drug. Follow applicable special handling and disposal procedures.1

Temozolomide capsules

Take temozolomide capsules at the same time each day. Administer temozolomide capsules consistently with respect to food (fasting vs. nonfasting) [see Clinical Pharmacology (12.3)]. To reduce nausea and vomiting, take temozolomide capsules on an empty stomach or at bedtime and consider antiemetic therapy prior to and following temozolomide capsules administration.

Swallow temozolomide capsules whole with water. Advise patients not to open, chew, or dissolve the contents of the capsules [see Warnings and Precautions (5.6)].

If capsules are accidentally opened or damaged, take precautions to avoid inhalation or contact with the skin or mucous membranes. In case of powder contact, wash the affected area with water immediately.
Cases of renal failure (including acute renal failure), some with a fatal outcome, have occurred in patients taking AFINITOR. Elevations of serum creatinine and proteinuria have been reported in patients taking AFINITOR/AFINITOR DISPERZ [see Adverse Reactions (6.1)]. The incidence of Grade 3 and 4 elevations of serum creatinine was up to 2% and up to 1%, respectively. The incidence of Grade 3 and 4 proteinuria was up to 1% and up to 0.5%, respectively. Monitor renal function prior to starting AFINITOR/AFINITOR DISPERZ and annually thereafter. Monitor renal function at least every 6 months in patients who have additional risk factors for renal failure.
Inactivated antigens are only used in parenterally administered vaccines for avian drugs. The only vaccine administered mucosally is a live vaccine, a modified live vaccine or an attenuated vaccine. However, live vaccines have several disadvantages including the risk of causing disease. The disclosed embodiments relate to a composition comprising inactivated bacterial and/or viral antigens formulated for transmucosal administration to avians, and methods of using the same. In certain embodiments, the composition comprises an inactivated Clostridium perfringens type a (Clostridium perfringens) antigen and/or a Salmonella antigen, such as an antigen from Salmonella kekuchii (Salmonella kentuckucky), Salmonella typhimurium (Salmonella typhimurium) and/or Salmonella enteritidis (Salmonella enteridis), or an escherichia coli (e.coli) antigen. The composition may comprise a polyacrylic acid adjuvant. The composition may be administered to the avian in ovo during the first 14 days post-hatch or after the first 14 days.
PURPOSE:A cream effective for skin diseases such as chaps, heat rashes, chilblains, etc. having no unpleasant feeling, convenient for use, handy to carry, and suitable for preservation, obtained by blending an oil of habu as a main component with peppermint oil and a proper amount of a hydrophilic ointment, heating the blend into a creamy state. CONSTITUTION:A mixed oil of an oil of habu in an oily state extracted from fats of internal organs of habu and peppermint oil (100:1) is blended with a proper amount of hydrophilic ointment (obtained by blending properly glycerin with sodium lauryl sulfate, stearyl alcohol, white vaseline, distilled water, etc.) at about 75 deg.C into a creamy state, to give a cream comprising an oil of habu as a main component. EFFECT:Unpleasant smell of habu of its own, greasiness, etc. can be eliminated.
Pain is one of the most frequent and persistent side effects of breast cancer treatment. Besides pain, breast cancer survivors (BCS) are prone to experience a myriad of other signs and symptoms related to altered somatosensory function, including for example, hypoesthesia, allodynia, and hyperalgesia, both at the local site of cancer and in remote body parts. Different breast cancer treatments can have a direct effect on somatosensory functioning, resulting in a wide range of these signs and symptoms. To our knowledge, currently no comprehensive overview exists on altered somatosensory functioning and resulting signs and symptoms in BCS with persistent pain. Investigating altered somatosensory functioning in this population could provide more insights in the underpinning pathophysiological mechanisms and consequently improve prevention and treatment in the future. Therefore, in this paper, first, normal somatosensory functioning is described. Second, quantitative sensory testing is presented as the recommend method to evaluate somatosensory functioning. Third, existing evidence on altered somatosensory functioning in BCS with persistent pain is summarized. Altered somatosensory functioning related to the most common cancer treatment modalities, including surgery and radiotherapy, hormone therapy, and chemotherapy are discussed. In addition, evidence on the presence of nociplastic pain as pain resulting from altered somatosensory functioning without evidence for nociception and/or neuropathy in BCS is summarized. At last, a discussion on this available evidence, limitations, and perspectives for clinical practice and for research are made.
This is a randomized, controlled open-label, parallel group study of 12 weeks duration aimed to examine the effectiveness of a local application of the kalahari melon (Citrullus lanatus) seed oil (S26E) for the healing of non-infected chronic (\>12 weeks) diabetic foot ulcers. The S26E is a natural extract rich in unsaturated (such as linoleic, oleic, palmitic and static) fatty acids which have shown promise in the promotion of wound healing by modulating the migration and functional properties of inflammatory cells in wound cites as well as the production of inflammatory cytokines. The safety of topical S26E application on human skin has been clinically demonstrated.

Eligible participants will be adults patients with diabetes mellitus (DM) type 1 or 2 and chronic (persistent for \>12 weeks after initial presentation) neuropathic or neuroischaemic non-infected diabetic foot ulcers. Following recruitment and randomization (on a 1:1 ratio) eligible patients will attend the study site on weekly intervals. After a run-in period of 2 weeks (visits 1-2) during which all participants will receive the optimal standard-of-care for neuropathic/neuroischaemic diabetic ulcers (incl. optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing) eligibility will be reassessed. Participants who will continue in the study will receive standard of care (control group) or standard of care plus daily local S26E application on ulcer (intervention group) (visits 3-12). After visit 12 the application of S26E will be terminated and all participants will receive an additional follow up visit 4 weeks later (final visit). Efficacy end-points will be assessed at the end of the of 12 weeks of observation (Visit 12)
The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
PCT No. PCT/GB92/01970 Sec. 371 Date Apr. 28, 1994 Sec. 102(e) Date Apr. 28, 1994 PCT Filed Oct. 27, 1992 PCT Pub. No. WO93/08837 PCT Pub. Date May 13, 1993A stabilized immunoglobulin composition comprises at least one immunoglobulin together with a stabilizing amount of a chelator of copper ions such as EDTA or citrate. Preferably the immunoglobulin is an antibody, for example, a recombinant CDR-grafted antibody. A process for enhancing the stability of an immunoglobulin comprises subjecting the immunoglobulin to a purification procedure capable of removing copper ions therefrom. Preferably, the immunoglobulin is rendered substantially free from detectable copper ions as determined, for example, by atomic absorption spectroscopy.
In the Basketing arm, a ureteral access sheath (UAS) will be placed per standard fashion. The ureteroscope will be introduced into the kidney and the stone fragmented at a setting of 0.8-1.0 J and 6-15 Hz. The resultant fragments will be basket extracted through the sheath for analysis. All fragments will be removed until no residual stone remains. At the time of UAS removal the ureter will be inspected. If there is no evidence of ureteral injury or swelling then a stent will be omitted.
Patients in this arm will only receive 4-8 cycles of cisplatin-based regimen. TPF ( docetaxel, cisplatin and 5-fluorouracil ), TP (docetaxel and cisplatin), GP (gemcitabine and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens are preferred.
Patient to be randomized to "exercise training group" will have exercise training sessions 2 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 75% of Vo2max.
Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis.